Although cohort studies which are based on intention-to-treat (ITT) approach offer a
simple design with data which are simpler to analyse and results easier to interpret,
such studies also intrinsically assume that any time-varying treatment effect that exits
can be adequately estimated by a fixed-effect component. However, such an
assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a
major strength of epidemiologic safety studies. The failure to properly reflect reality may
result in effect under-estimation leading to false and irreproducible conclusions due to
exposure misclassification. In effect, the use of nested case-control design is a
concession that ITT in cohort design may not be adequate. But the nested design also
has its own sources of bias, including confounding by indication. We present an
overview of the counter-matched version of the nested case-control, case-crossover,
case-in-time, case series and case-cohort designs as alternatives in prospective postauthorization safety studies.